IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0226196.html
   My bibliography  Save this article

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France

Author

Listed:
  • Marine Sivignon
  • Rémi Monnier
  • Bertrand Tehard
  • Stéphane Roze

Abstract

The aim of the study is to evaluate the cost-effectiveness of alectinib for first-line treatment of ALK+ advanced non-small-cell lung cancer compared to crizotinib in the French setting. This study used a partitioned survival model, with three discrete health states (progression-free survival, post-progression survival and death). Survival probabilities were derived from a randomised Phase III clinical trial comparing alectinib to crizotinib (ALEX). Beyond the length of the trial (18 months), the efficacy of both treatments was considered equivalent. Occurrence of adverse events or brain metastases were considered as inter-current events. Utilities (and disutilities for intercurrent adverse events) derived from the EQ-5D were applied. Costs were attributed using standard French national public health tariffs. Projected mean overall survival was 4.62 years for alectinib and 4.18 years for crizotinib. Projected mean progression-free survival was 30.30 months for alectinib and 16.13 months for crizotinib. The total number of quality-adjusted life years projected was 3.40 for alectinib and 2.84 for crizotinib. The projected total cost of treatment over the lifetime of the model was € 246,022 for alectinib and € 195,486 for crizotinib. This extra cost was principally attributable to treatment acquisition costs and management before progression. Alectinib was associated with lower costs related to brain metastases and to management post-progression. The incremental cost per life year gained was 115,334 €/year and the incremental cost-effectiveness ratio was 90,232 €/QALY. First-line treatment of ALK+ NSCLC with alectinib provides superior clinical outcomes to crizotinib and is cost-effective in the French context.

Suggested Citation

  • Marine Sivignon & Rémi Monnier & Bertrand Tehard & Stéphane Roze, 2020. "Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-14, January.
    • Handle: RePEc:plo:pone00:0226196
    DOI: 10.1371/journal.pone.0226196
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0226196
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0226196&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0226196?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Julie Chevalier & Gérard Pouvourville, 2013. "Valuing EQ-5D using Time Trade-Off in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 57-66, February.
    2. Elizabeth Wehler & Zhongyun Zhao & S. Pinar Bilir & Julie Munakata & Beth Barber, 2017. "Economic burden of toxicities associated with treating metastatic melanoma in eight countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(1), pages 49-58, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Marguerite Kandel & Aurélie Bardet & Stéphane Dalle & Clara Allayous & Laurent Mortier & Bernard Guillot & Caroline Dutriaux & Marie-Thérèse Leccia & Sophie Dalac & Henri Montaudié & Philippe Saiag & , 2022. "Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France," Post-Print hal-04049403, HAL.
    2. Karine Chevreul & Coralie Gandré & Karen Berg Brigham & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schiep, 2016. "Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 43-52, April.
    3. Mathieu F. Janssen & A. Simon Pickard & James W. Shaw, 2021. "General population normative data for the EQ-5D-3L in the five largest European economies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1467-1475, December.
    4. Manuel B. Huber & Julia Felix & Martin Vogelmann & Reiner Leidl, 2017. "Health-Related Quality of Life of the General German Population in 2015: Results from the EQ-5D-5L," IJERPH, MDPI, vol. 14(4), pages 1-12, April.
    5. Gregoire Mercier & Jenica Pastor & Valerie Clément & Ulysse Rodts & Christine Moffat & Isabelle Quéré, 2019. "Out-of-pocket payments, vertical equity and unmet medical needs in France: A national multicenter prospective study on lymphedema," PLOS ONE, Public Library of Science, vol. 14(5), pages 1-13, May.
    6. Lotte Westerink & Jelmer L. J. Nicolai & Carl Samuelsen & Hans J. M. Smit & Pieter E. Postmus & Ingolf Griebsch & Maarten J. Postma, 2020. "Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(6), pages 931-943, August.
    7. Laurène Gautier & Jessica Azzi & Grèce Saba & Geneviève Bonnelye & Gérard Pouvourville, 2023. "Population norms in France with EQ-5D-5L: health states, value indexes, and VAS," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(9), pages 1517-1530, December.
    8. Tessier, Philippe & Blanchin, Myriam & Sébille, Véronique, 2017. "Does the relationship between health-related quality of life and subjective well-being change over time? An exploratory study among breast cancer patients," Social Science & Medicine, Elsevier, vol. 174(C), pages 96-103.
    9. Grégoire Mercier & Jenica Pastor & Valérie Clément & Ulysse Rodts & Christine Moffat & Isabelle Quéré, 2019. "Out-of-pocket payments, vertical equity and unmet medical needs in France: A national multicenter prospective study on lymphedema," Post-Print hal-02862217, HAL.
    10. Marian Sorin Paveliu & Elena Olariu & Raluca Caplescu & Yemi Oluboyede & Ileana-Gabriela Niculescu-Aron & Simona Ernu & Luke Vale, 2021. "Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off," IJERPH, MDPI, vol. 18(14), pages 1-16, July.
    11. Fan Yang & Carlos K. H. Wong & Nan Luo & James Piercy & Rebecca Moon & James Jackson, 2019. "Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(8), pages 1195-1206, November.
    12. Julie Chevalier & Catherine Chamoux & Florence Hammès & Annie Chicoye, 2016. "Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-12, March.
    13. Anne Spencer & Ewan Tomeny & Ruben E. Mujica-Mota & Angela Robinson & Judith Covey & Jose Luis Pinto-Prades, 2019. "Do time trade-off values fully capture attitudes that are relevant to health-related choices?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(4), pages 559-568, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0226196. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.